Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Study results in three new co-amorphous drug systems with great anti-COVID-19 potential

Researchers demonstrated that the bioavailability of matrine-type alkaloids could be prolonged by employing a co-former, resveratrol.

15 Mar 2022

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in Phase I clinical trial evaluating ISM001-055, the first anti-fibrotic small molecule inhibitor generated by Insilico's AI-powered drug discovery platform for idiopathic pulmonary fibrosis (IPF).

24 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Trial of early antiviral therapy for COVID-19 shows no significant benefit

A new preprint research paper examines the efficacy of using three antivirals in various combinations in early infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Feb 2022

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

AI systems may one day assist anesthesiologists in the operating room, study suggests

A new study by researchers at MIT and Massachusetts General Hospital suggests the day may be approaching when advanced artificial intelligence systems could assist anesthesiologists in the operating room.

6 Feb 2022

Nanomedicine can be improved with proper and more predictive in vitro assays

Messenger RNA (mRNA) vaccines are a prime example of the promising field of nanomedicine. But progress in the design and application of nanoparticles as efficient delivery vehicles for biopharmaceutics containing nucleic acid or protein drug substances is, unfortunately, remarkably slow.

1 Feb 2022

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

In a new study, a team of researchers discovered S-217622, a non-covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate for the treatment of COVID-19.

31 Jan 2022

New study offers valuable information on ocular drug metabolism and pharmacokinetics

Severe visual illnesses are increasing in our society, and effective treatments are missing for diseases as age-related macular degeneration, diabetic retinopathy, and glaucoma. Both industry and academia are highly interested to advance ocular drug discovery and development.

29 Jan 2022

The latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2

A recent review discusses the engineering versatility of polymeric nanoparticles - making a good therapeutic alternative against coronavirus diseases.

19 Jan 2022

Topical antiseptic Acriflavine inhibits SARS-CoV-2 and other betacoronaviruses

A new study, published in the journal Cell Chemical Biology, has reported the discovery of acriflavine (ACF), an effective inhibitor of SARS-CoV-2. This drug is a mixture of trypaflavines (3,6-diamino-10-methylacridinium chloride and 3,6-diamino-3-methylacridinium chloride) and proflavine (3,6-diaminoacridine).

16 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

New drug targeting LF and onchocerciasis begins its first in human trial in Liverpool

A new drug developed by an LSTM led partnership, which targets the neglected tropical diseases lymphatic filariasis and onchocerciasis has begun its first in human trial.

6 Jan 2022

Novel AI-based system models the progression of chronic diseases as patients age

Using artificial intelligence, a team of University at Buffalo researchers has developed a novel system that models the progression of chronic diseases as patients age.

7 Dec 2021

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

A recent study reports neutralizing efficacy for a fused peptide-antibody molecule against SARS-CoV-2, providing hope that therapeutic neutralizing antibodies may soon be available.

3 Dec 2021

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.

2 Dec 2021

Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System

CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.

From CN-Bio 1 Dec 2021

$Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients$

Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients.

29 Nov 2021